Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25545637 | 1.00 | MAPK1 (0.33) | MAPK1PDE10AFFAR1PRKAB2PRKAG1 | |
| SCHEMBL23896105 | 0.93 | PDE10A (0.33) | MAPK1PDE10AFFAR1PRKAB2PRKAG1 | |
| SCHEMBL25549205 | 0.90 | FFAR1 (0.35) | PDE10AFFAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25544024 | 0.90 | FFAR1 (0.35) | PDE10AFFAR1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL25545515 | 0.89 | ESR1 (0.37) | PDE10APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23896327 | 0.89 | ESR1 (0.37) | PDE10APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23896329 | 0.89 | ESR1 (0.37) | PDE10APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL25545640 | 0.85 | PDE10A (0.35) | PDE10APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23896150 | 0.85 | PDE10A (0.35) | PDE10APRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23906166 | 0.85 | SGK1 (0.35) | MAPK1FFAR1PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2021203028-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | MAPK1 1773/4885PDE10A 3701/4885FFAR1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.